G. A. Otterson

Statistics

Publications

Citations

164

H-Index

Active since

2000

Affiliations

The Ohio State University(Current)

Vanderbilt University

Providence Portland Medical Center

G. A. Otterson is an author at The Ohio State University specializing in oncology, lung cancer pharmacotherapy, and non-small cell lung cancer therapy.

Publications per year

2000–2014

Publications

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non–Small-Cell Lung Cancer

Martin J. Edelman, Ming Tan, Mary J. Fidler et al. · Journal of Clinical Oncology · 2014 · 45 citations

Medicine, Oncology, Pharmacology +15

An epigenetic mechanism for capecitabine resistance in mesothelioma

Kavitha Kosuri, Xin Wu, Liang Wang et al. · Biochemical and Biophysical Research Communications · 2009 · 43 citations

Medicine, Cancer Biology, Oncology +14

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer

Barbara J. Gitlitz, Eric Bernstein, Edgardo S. Santos et al. · Journal of Thoracic Oncology · 2014 · 35 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

Sundar Ramalingam, Julien Mazières, David Planchard et al. · International Journal of Radiation Oncology*Biology*Physics · 2014 · 19 citations

Pharmacy, Oncology, Pharmacotherapy +12

Phase II study of oxaliplatin (O) and paclitaxel (T) in advanced Non-Small Cell Lung Cancer (NSCLC)

Ann M. Mauer, G. A. Otterson, Livia L. Szeto et al. · Lung Cancer · 2000 · 12 citations

Medicine, Oncology, Pharmacology +14

1–5 of 6